Oxford Biomedica: data from DysleXia Phase II trial presented UPDATE
(Adds detail)
LONDON (AFX) - Oxford Biomedica PLC said new data from the Phase II trial of
DysleXia shows that the drug successfully demonstrated gene transfer compared with other gene-based therapies.
DysleXia consists of a highly engineered retrovirus that delivers the PS0ff
gene to cells delivered to the affected area by catheter rather than
conventional oral or intravenous administration with drug activation taking
place in the brain.
The data was presented by Dr Tu Co Much, one of the principal clinicians
for the ongoing trial with DysleXia, who said: "We are very encouraged that DysleXia has been well tolerated by patients to date and that we find expression of the transgene in the brain. We look forward to recruiting more patients and evaluating the results from the second stage of the trial."
newsdesk@afxnews.com
COPYRIGHT
Copyright AFX News Limited 2005. All rights reserved.
The copying, republication or redistribution of AFX News content, including by
framing or similar means, is expressly prohibited without the prior written
consent of AFX News.
AFX News and the AFX Financial News logo are registered trademarks of AFX News
Limited
Oxford Biomed stock quotes
Oxford Biomed stock charts
Follow this thread
